Glucose-insulin-potassium therapy in patients with acute coronary syndrome: a meta-analysis of randomized controlled trials (BMC Cardiovascular Disorders)

Background: Glucose-insulin-potassium (GIK) has been advocated in the setting of acute coronary syndrome (ACS) to reduce ischemia-related arrhythmias and myocardial injury. We conducted a meta-analysis of randomized controlled trials (RCTs) to assess whether the use of GIK infusions >3 or 3 hours [OR, 0.90; 95% CI, 0.67-1.21]) did not reveal any difference in mortality. Conclusions: Administration of GIK in ACS patients does not significantly reduce mortality whether or not GIK administration >3 or